title: Reply to Young, Ochi, and Marimuthu.
authors.affiliation: Department of Pharmacy, Wake Forest Baptist Health.
authors.forename: John C
authors.initials: JC
authors.lastname: Williamson
authors.affiliation: Department of Pharmacy, Wake Forest Baptist Health.
authors.forename: Haley G
authors.initials: HG
authors.lastname: Gibbs
authors.affiliation: Department of Internal Medicine, Section on Infectious Diseases, Winston-Salem, North Carolina.
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Ohl
authors.affiliation: Department of Pharmacy, Wake Forest Baptist Health.
authors.forename: James W
authors.initials: JW
authors.lastname: Johnson
authors.affiliation: Department of Pharmacy, Wake Forest Baptist Health.
authors.forename: James R
authors.initials: JR
authors.lastname: Beardsley
authors.affiliation: Department of Internal Medicine, Section on Infectious Diseases, Winston-Salem, North Carolina.
authors.forename: Vera P
authors.initials: VP
authors.lastname: Luther
authors.affiliation: Department of Pharmacy, Maine Medical Center, Portland.
authors.forename: Kristina E E
authors.initials: KE
authors.lastname: Rokas
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage*; D016360:Clostridioides difficile / Q000302:isolation & purification*; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000890:Anti-Infective Agents; D008795:Metronidazole; D014640:Vancomycin